# OnCo record eli-002-7p (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/eli-002-7p/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "eli-002-7p" ;
  schema:name "ELI-002 7P"@en ;
  schema:description "A ready-made vaccine against the seven commonest KRAS mutations, given after pancreatic cancer surgery. Its phase 2 missed the main goal in 2026 but showed signs of activity."@en ;
  schema:url <https://onco.cc/drugs/eli-002-7p/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://elicio.com/press_releases/elicio-therapeutics-reports-results-from-phase-2-amplify-7p-study-and-outlines-refined-phase-3-development-strategy-for-eli-002-7p-in-adjuvant-pancreatic-cancer/> ;
  onco:status "phase-2" ;
  onco:modality "Off-the-shelf lymph-node-targeted KRAS peptide vaccine" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/shared-antigen-vaccine/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/elicio-therapeutics/> ;
  onco:trials <https://onco.cc/trials/amplify-7p/> .